查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1425109

新生儿筛检市场 – 2024-2029 年预测

Newborn Screening Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022年新生儿筛检产业的市场规模为1,026,817,000美元，预计在预测期内复合年增长率为8.31%。

新生儿筛检用于识别可能影响儿童长期健康的各种状况。一系列测试主要涉及筛检技术，以便及时发现、健康管理和早期诊断，防止整体残疾。这些测试可检测儿童的发育、遗传和代谢疾病。新生儿筛检是在出院前从婴儿脚跟抽取几滴血液检查是否有严重的先天性心臟疾病。

新生儿筛检市场的驱动因素

由于政府倡议的不断增加和筛检技术的各种发展，新生儿筛检市场预计将成长。高出生率和新生儿疾病盛行率增加是影响经济成长的其他一些主要因素。此外，印度等新兴市场的遗传疾病筛检为主要企业提供了主要的市场成长机会。出生率的上升和可支配收入的增加也推动了新生儿筛检市场的发展

干血斑检测预计将占据最大的市场占有率

预计干血检测将在预测期内主导新生儿筛检产业。这些测试用于先天性代谢紊乱的检测已有 50 多年的历史。干血测试是有利的，因为它们很容易用脚后跟棒或手指取样，需要的量极少，并且易于运输。白血病、淋巴瘤和自闭症可以透过干血测试来检测。干血检测的优点是可以采集小样本且易于运输。因此，新生儿疾病数量的增加正在推动新生儿筛检市场的发展。

快速发展的新药管道

新药和生技药品的研发管线正在迅速扩大。例如，Zolgensma 是第一个用于新生儿筛检疾病的基因治疗药物，在 Spinraza 获得 FDA核准后不久就上市了。 SMA因此被纳入国家统计局。由于这些药物非常稀有，因此药物变得非常昂贵的可能性仍然是一个威胁。例如，Zolgensma 每剂成本约为 220 万美元。此外，政府、家庭和医疗保健专业人员的责任对于制定各种新生儿筛检计画至关重要。此外，主要的新生儿筛检市场领导正在关注新药的产品创新。

政府加大力度

政府不断采取的倡议正在推动新生儿筛检市场的成长。例如，世界卫生组织（WHO）建议在全球范围内实施新生儿筛检计划，以保护儿童的健康。美国卫生与公众服务部新生儿和儿童遗​​传性疾病部长咨询委员会 (PEACH) 和众多倡导团体已製定了多项政策和指南。资金筹措的增加和需要筛检的各种疾病是推动市场成长的主要因素。

在北美，新生儿筛检市场预计将稳定成长。

由于许多国家先天性疾病盛行率的增加和检测力度的加强，预计北美的新生儿筛检市场在预测期内将会成长。所有北美国家都致力于新生儿筛检计划。筛检标准由美国医学遗传学学院 (ACMG) 透过广泛研究提供，该学院由美国卫生与公众服务部监督。此外，为了提高家长的认识，美国卫生署发布了免费资料并创建了一个网站。

主要市场公司的成长策略

新生儿筛检公司正专注于发展其生产设施并进行各种併购活动，以加强其在新生儿筛检市场的地位。例如，2022 年 8 月，Perkin Elmer 将其应用、食品和企业业务出售给 New Mountain Capital, LLC。赔偿总额为24.5亿美元。新生儿筛检产业的公司也将先进技术和创新融入各种产品中，以满足消费者的需求。此外，公共和私人机构之间也开展新生儿筛检合作。

新生儿筛检产品

  • Panthera PuncherTM 9：下一代干式样品冲压工具 Panthera PuncherTM 9 由 PerkinElmer 製造。 PerkinElmer 作为新生儿筛检领域的先驱，选择了必要的技术选项和材料来确保冲压完美。
  • EONISTM Q384：EONISTM Q 384 孔版仪器采用易于理解且独特的工作流程创建，使 qPCR 培训和部署变得轻鬆。
  • VARIANT NBS新生儿筛检系统：VARIANTnbs 已成为新生儿筛检镰状贫血等血红蛋白异常的事实上的标准。它具有全自动分析和最先进的结果报告，可实现最佳效果。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章新生儿筛检市场：依技术分类

  • 介绍
  • 免疫测定和酵素测定
  • 串联式质谱法
  • 分子测定
  • 听力筛检技术
  • 其他的

第六章新生儿筛检市场：通过测试

  • 介绍
  • 干血斑试验
  • 听力筛检测试
  • CCHD筛检测试

第七章新生儿筛检市场：依最终用户分类

  • 介绍
  • 临床实验室
  • 医院

第八章新生儿筛检市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第十章 公司简介

  • Perkin Elmer
  • Trivitron Healthcare
  • LifeCell International
  • Bio-Rad
  • Apollo Cradle
  • Nemours Children's Health
  • March for Dimes
  • Cure SMA
  • Igenomix India
简介目录
Product Code: KSI061616217

The newborn screening industry was valued at US$1,026.817 million in 2022 and is expected to grow at a CAGR of 8.31% during the forecast period.

Newborn screening is utilized to identify various conditions that affect the child's long-term health. A series of tests are involved in the screening technology mainly timely detection, health management, and early diagnosis to prevent overall disability. These tests detect developmental, genetic, and metabolic disorders in children. Newborn screening is performed by using a few drops of blood from the newborn's heel and are tested for critical congenital heart defects before discharge from hospitals.

Driving factors for the newborn screening market

The newborn screening market is anticipated to grow owing to rising government initiatives and various developments in screening technology. High birth rates and an increase in the prevalence of neonatal disease are some of the other key factors influencing the growth. Furthermore, the screening of genetic disorders in developing nations like India provides significant newborn screening market growth opportunities for key players. An increase in birth rate and disposable income is also fueling the newborn screening market

Dried blood spot tests are anticipated to hold the maximum market share

Dried blood tests are predicted to dominate the newborn screening industry during the forecast period. These tests have been used for congenital metabolic diseases for over 50 years. Dried blood tests are advantageous due to ease of sample attainment by finger of heel stick, include minimal volume requirements, and are easier to transport. Leukemia, lymphomas, and autism can be detected using the dried blood test. It offers the advantage of collecting small sample volumes which are easier to transport. Therefore, the rising number of diseases in newborns is fueling the newborn screening market.

Rapidly developing pipeline of novel medicines

The pipeline of novel medicines and biologics is quickly expanding. For instance, the first gene therapy for newborn screening disorder, Zolgensma was made accessible shortly after Spinraza was approved by the FDA. This resulted in the inclusion of SMA in the NBS. Since these medicines are very uncommon, the possibility of the medications being very expensive is still a threat. For instance, Zolgensma costs around $2.2 million for a one-dose therapy. Additionally, for the creation of various newborn screening programs, the responsibilities of government, families, and healthcare professionals have been crucial. Furthermore, major newborn screening market leaders are focusing on product innovation for novel medicines.

Increasing government initiatives

Growth in government initiatives is fueling the newborn screening market growth. For instance, the World Health Organization recommended newborn screening programs to safeguard children's health globally. Numerous policies and guidelines were taken by the U.S. Department of Health and Human Services Secretary's Advisory Committee on Heritable Disorders in Newborns and Children, UK (PEACH), and many advocacy groups. Increasing funding and various conditions requiring screening are the key factors contributing to the growth of the market.

In North America, it is projected that the newborn screening market will grow steadily.

The newborn screening market is anticipated to grow in North America during the projected period due to the increasing prevalence of congenital disorders and enforced testing in many nations. All the North American nations diligently follow the newborn screening programs. Through extensive research by the American College of Medical Genetics (ACMG) which is done under the supervision of the U.S. Department of Health and Human Services, the screening conditions are provided. Additionally, to raise awareness among parents the health departments of the United States have released free data and created websites.

Growth strategies by major market players

The newborn screening companies are focusing on growing their manufacturing facilities and are engaging in various merger and acquisition activities to strengthen their newborn screening market position. For instance, in August 2022, Perkin Elmer sold its Applied, Food, and Enterprise business to New Mountain Capital, LLC. With a total compensation of $2.45 billion. The newborn screening industry players have also been involved in various product innovations owing to the incorporation of advanced technology and meeting consumer requirements. Additionally, collaborations are being done between public and private organizations for newborn screening.

Newborn Screening Products

  • Panthera PuncherTM 9, The next generation Panthera PuncherTM 9 dry sample punching tool is manufactured by PerkinElmer. PerkinElmer, a pioneer in newborn screening, has chosen the technological options and materials required to guarantee a new benchmark for punching perfection.
  • EONISTM Q384, The EONISTM Q 384-well version instrument was created with a straightforward and distinctive workflow, making qPCR training and deployment simple to carry out. The EONISTM Q promises a turnaround time of under two hours and doesn't require a clean room because of the streamlined procedure.
  • VARIANT NBS Newborn Screening System, The VARIANTnbs has become the de facto standard for automated newborn screening for hemoglobin abnormalities such as sickle cell anemia. For optimal effectiveness, it has completely automated analysis and cutting-edge result reporting.

Market Key Developments

  • In July 2023, At the AMTZ Campus in Vishakhapatnam, India, a Centre of Excellence (CoE) with cutting-edge R&D and manufacturing capabilities was established by Triviton Healthcare.
  • In June 2023, To educate the medical teams working under Rashtriya Bal Swasthya Karyakram (RBSK) and District Early Intervention Centre (DEIC) on screening for communication disorders in children, the Department of Health and Family Welfare and the All India Institute of Speech and Hearing (AIISH), based in Mysuru, have partnered to expand the Newborn Screening Programme (NBS).
  • In June 2022, according to a novel program announced by Rady Children's Institute for Genomic Medicine BeginNGSTM is being used to screen newborns for roughly 400 genetic diseases for which there are known treatments using rapid whole genome sequencing.

Segmentation:

By Technology

  • Immune Assays & Enzymatic Assays
  • Tandem Mass Spectrometry
  • Molecular Assays
  • Hearing Screening Technologies
  • Others

By Test

  • Dry Blood Spot Tests
  • Hearing Screening Tests
  • CCHD Screening Tests

By End-User

  • Clinical Laboratories
  • Hospitals

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. NEWBORN SCREENING MARKET, BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Immune Assays & Enzymatic Assays
  • 5.3. Tandem Mass Spectrometry
  • 5.4. Molecular Assays
  • 5.5. Hearing Screening Technologies
  • 5.6. Others

6. NEWBORN SCREENING MARKET, BY TEST

  • 6.1. Introduction
  • 6.2. Dry Blood Spot Tests
  • 6.3. Hearing Screening Tests
  • 6.4. CCHD Screening Tests

7. NEWBORN SCREENING MARKET, BY END-USER

  • 7.1. Introduction
  • 7.2. Clinical Laboratories
  • 7.3. Hospitals

8. NEWBORN SCREENING MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Perkin Elmer
  • 10.2. Trivitron Healthcare
  • 10.3. LifeCell International
  • 10.4. Bio-Rad
  • 10.5. Apollo Cradle
  • 10.6. Nemours Children's Health
  • 10.7. March for Dimes
  • 10.8. Cure SMA
  • 10.9. Igenomix India